Stay updated with breaking news from Nuclear Export. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) has received a consensus rating of “Moderate Buy” from the five research firms that are presently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12-month price objective […]
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...
Kennedy Investment Group raised its holdings in Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Free Report) by 75.0% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 35,000 shares of the company’s stock after buying an additional 15,000 shares during the quarter. Kennedy Investment Group’s holdings in […]
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...
Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) has been given an average recommendation of “Moderate Buy” by the five ratings firms that are covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price target among […]